[go: up one dir, main page]

WO2007135684A3 - Procédé de traitement d'auto-immunité anti-cd4 - Google Patents

Procédé de traitement d'auto-immunité anti-cd4 Download PDF

Info

Publication number
WO2007135684A3
WO2007135684A3 PCT/IL2007/000627 IL2007000627W WO2007135684A3 WO 2007135684 A3 WO2007135684 A3 WO 2007135684A3 IL 2007000627 W IL2007000627 W IL 2007000627W WO 2007135684 A3 WO2007135684 A3 WO 2007135684A3
Authority
WO
WIPO (PCT)
Prior art keywords
cell mediated
amino acids
stretch
autoimmunity
elicit
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IL2007/000627
Other languages
English (en)
Other versions
WO2007135684A2 (fr
Inventor
Rivka Abulafia-Lapid
Henri Atlan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hadasit Medical Research Services and Development Co
Original Assignee
Hadasit Medical Research Services and Development Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hadasit Medical Research Services and Development Co filed Critical Hadasit Medical Research Services and Development Co
Publication of WO2007135684A2 publication Critical patent/WO2007135684A2/fr
Anticipated expiration legal-status Critical
Publication of WO2007135684A3 publication Critical patent/WO2007135684A3/fr
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70514—CD4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Peptides ou polypeptides comprenant une suite d'acides aminés contigus qui comportent au moins 5 acides aminés chevauchant une suite correspondante de protéine CD4, et cette suite d'acides aminés est capable d'induire une réponse auto-immune à médiation assurée par lymphocytes T contre les lymphocytes T CD4+ chez un patient avec auto-immunité dont la médiation est assurée par les lymphocytes T, ou, chez un tel patient, d'amener le peptide ou polypeptide considéré à induire une telle réponse. On décrit aussi diverses applications de ces peptides et polypeptides dans la thérapie et le diagnostic.
PCT/IL2007/000627 2006-05-22 2007-05-24 Procédé de traitement d'auto-immunité anti-cd4 Ceased WO2007135684A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US80212506P 2006-05-22 2006-05-22
US60/802,125 2006-05-22

Publications (2)

Publication Number Publication Date
WO2007135684A2 WO2007135684A2 (fr) 2007-11-29
WO2007135684A3 true WO2007135684A3 (fr) 2009-04-23

Family

ID=38723699

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IL2007/000627 Ceased WO2007135684A2 (fr) 2006-05-22 2007-05-24 Procédé de traitement d'auto-immunité anti-cd4

Country Status (1)

Country Link
WO (1) WO2007135684A2 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2476436T (pt) 2006-08-11 2018-02-23 Life Sciences Res Partners Vzw Péptidos imunogénicos e a sua utilização em distúrbios imunitários
ES2676630T3 (es) 2008-02-14 2018-07-23 Life Sciences Research Partners Vzw Control inmunogénico de tumores y células tumorales
EP2719396B1 (fr) 2008-02-14 2017-06-21 Life Sciences Research Partners VZW Immunothérapie ciblant les agents pathogènes intracellulaires
WO2009121690A1 (fr) 2008-03-13 2009-10-08 Biotest Ag Agent pour traiter une maladie
ES2610327T3 (es) 2008-03-13 2017-04-27 Biotest Ag Régimen de dosificación de anticuerpos anti-CD4 para el tratamiento de enfermedades autoinmunitarias
MX2010010026A (es) 2008-03-13 2011-03-21 Biotest Ag Agente para tratar enfermedad.
WO2010092185A2 (fr) * 2009-02-16 2010-08-19 Institut National De La Sante Et De La Recherche Medicale (Inserm) Inhibiteurs de l'intération scramblase/cd4 pour le traitement d'infections à lentivirus
GB0920944D0 (en) * 2009-11-30 2010-01-13 Biotest Ag Agents for treating disease
HUE055070T2 (hu) * 2010-11-25 2021-10-28 Imnate Sarl Immunogén peptidek fertõzõ betegségek, autoimmun betegségek, allofaktorokra adott immunválaszok, allergiás betegségek, tumorok, graftkilökõdés, és génterápiához vagy génvakcinációhoz alkalmazott vírusvektorokkal szembeni immunválaszok megelõzésében és/vagy kezelésében történõ alkalmazásra
GB201201511D0 (en) 2012-01-30 2012-03-14 Univ Leuven Kath Modified epitopes for boosting CD4+ T-cell responses
GB201309469D0 (en) 2013-05-28 2013-07-10 Imcyse Sa Detection of CD4+ T lymphocytes
GB201418433D0 (en) 2014-10-17 2014-12-03 Imcyse Sa Novel immunogenic peptides
US10729791B2 (en) 2015-05-18 2020-08-04 Imcyse Sa Animal models for evaluating pharmaceutical compounds
EP3352782B1 (fr) 2015-09-25 2021-03-31 ImCyse SA Composés et procédés améliorés permettant de supprimer des réponses immunitaires à des agents thérapeutiques
CN109069605B (zh) 2016-04-19 2022-11-29 易姆赛斯股份公司 新免疫原性CD1d结合肽

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ABULAFIA-LAPID ET AL.: "T-cell vaccination against anti-CD4 autoimmunity in HIV-1 infected patients", JOURNAL OF CLINICAL VIROLOGY, 2004, pages 31S, S48 - S54 *
ABULAFIA-LAPID ET AL.: "T-cell vaccination against anti-CD4 autoimmunity in HIV-1 subtypes B and C-infected patients-An extended open trial", VACCINE, vol. 23, 2005, pages 2149 - 2153 *
ATLAN ET AL.: "Can AIDS be prevented by T-cell vaccination", IMMUNOLOGY TODAY, vol. 14, no. 5, 1993, pages 200 - 202 *
ATLAN ET AL.: "Mechanisms of autoimmunity and AIDS: prospects for therapeutic intervention", RES. IMMUNOLOGY, vol. 145, 1994, pages 165 - 183 *

Also Published As

Publication number Publication date
WO2007135684A2 (fr) 2007-11-29

Similar Documents

Publication Publication Date Title
WO2007135684A3 (fr) Procédé de traitement d'auto-immunité anti-cd4
WO2007146269A3 (fr) Fragments peptidiques destinés à induire la synthèse de protéines matricielles extracellulaires
ATE542896T1 (de) Mit dpp-iv hemmenden peptiden angereichertes proteinhydrolysat und deren verwendung
NZ591612A (en) Prevention, treatment and diagnosis of p.gingivalis infection with peptides
PH12012502372A1 (en) Hla-a*3303-restricted wt1 peptide and pharmaceutical composition comprising the same
WO2003087768A3 (fr) Cibles pour une intervention therapeutique identifiee dans le proteome mitochondrial
WO2007047829A3 (fr) Nouvelles protéines hétérodimères et utilisations de celles-ci
EP3412680A3 (fr) Nouveaux peptides qui se lient à des types de mhc de classe ii et leur utilisation dans le diagnostic et le traitement
WO2006001023A3 (fr) Proteines chimeres et utilisations associees
WO2022272033A8 (fr) Protéines de contact avec des cellules immunitaires à libération prolongée et procédés de traitement
NZ595387A (en) Peptides for treatment and diagnosis of autoimmune disease
EP4566622A3 (fr) Polypeptides de fusion dap10/dap12
WO2004009625A3 (fr) Peptides et derives de peptides destines au traitement des maladies liees a ?-synucleine
WO2006061101A3 (fr) Peptides d'administration medicamenteuse
ATE474589T1 (de) Angiogene peptide und ihre verwendungen
WO2004005317A3 (fr) Dimeres derivant de la thrombine
WO2002070665A3 (fr) Hybrides recombines d'allergenes a allergenicite reduite conservant l'immunogenicite des allergenes naturels
WO2007135268A3 (fr) Utilisation de peptides en tant que principes actifs amincissants
WO2003015825A3 (fr) Conjugue
WO2008010096A3 (fr) Procédé de préparation de polypeptides mycobactériens recombinés de levure et leur utilisation pour diagnostiquer des maladies associées à des mycobactéries
NZ597470A (en) Therapeutic peptides, polypeptides ans nucleic acid sequences
NZ591827A (en) Biologically active peptides comprising PTTKTYFPHF and their uses in the manufacture of a medicament for modulating immune reaction in a radiotherapy-induced immuno-compromised subject
NZ335136A (en) Isolated peptides which complex with hla-cw*16 molecules, and uses thereof
WO2002036628A3 (fr) Nouveaux polypeptides $g(b) interferon multimeres
EP4414384A3 (fr) Proteine recombinante

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07736367

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07736367

Country of ref document: EP

Kind code of ref document: A2